Discordant dMMR/IHC Status Correlates With Improved Treatment Outcomes in CRC and Endometrial Cancer

Amin Nassar, MD, and Elias Bou Farhat, MD, spotlight a study evaluating the accuracy and sensitivity of NGS mutation signature in assessing MMR status vs IHC testing.

Patients with mismatch repair–deficient, immunohistochemistry-intact colorectal cancer or endometrial cancer benefit from immune checkpoint inhibitors.

Amin Nassar, MD, discusses the investigation of NGS plus standard IHC to detect dMMR status in patients with colorectal cancer or endometrial cancer.

Drs Nassar and Bou Farhat explain how tumor-only NGS could address the limitations of IHC testing for MMR mutation signatures across several tumor types.

Elias Bou Farhat, MD, discusses an investigation of NGS sensitivity vs standard IHC alone in the assessment of dMMR colorectal cancer or endometrial cancer.